HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − June 30, 2018
Data through : June 30, 2018
Table 4 − Progression to Step 2 by Site

	Overall	Baylor	Blantyre	Botha's Hill	DTTC−SU
Total Participants Enrolled[1]	151	0	0	0	0
Participants who have been enrolled for 6 weeks or received injection[2]	149	0	0	0	0
Progressed to Step 2	142/149 (95.3%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Progression Status Pending	4/149 (2.7%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Did Not Progress to Step 2	3/149 (2.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product	2/149 (1.3%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Terminated from the study	1/149 (0.7%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product first and then terminated from the study	0/149 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/0 (−%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (30JUN2018,5:32)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − June 30, 2018
Data through : June 30, 2018
Table 4 − Progression to Step 2 by Site

	Emavundleni	Gaborone	Isipingo	Kisumu	Lilongwe
Total Participants Enrolled[1]	0	12	0	0	0
Participants who have been enrolled for 6 weeks or received injection[2]	0	12	0	0	0
Progressed to Step 2	0/0 (−%)	10/12 (83.3%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Progression Status Pending	0/0 (−%)	0/12 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Did Not Progress to Step 2	0/0 (−%)	2/12 (16.7%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product	0/0 (−%)	2/12 (16.7%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Terminated from the study	0/0 (−%)	0/12 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (−%)	0/12 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (30JUN2018,5:32)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − June 30, 2018
Data through : June 30, 2018
Table 4 − Progression to Step 2 by Site

	MU−JHU	Parirenyatwa	Seke South	Soweto	Spilhaus
Total Participants Enrolled[1]	0	25	0	33	0
Participants who have been enrolled for 6 weeks or received injection[2]	0	25	0	33	0
Progressed to Step 2	0/0 (−%)	23/25 (92.0%)	0/0 (−%)	32/33 (97.0%)	0/0 (−%)
Progression Status Pending	0/0 (−%)	2/25 (8.0%)	0/0 (−%)	0/33 (0.0%)	0/0 (−%)
Did Not Progress to Step 2	0/0 (−%)	0/25 (0.0%)	0/0 (−%)	1/33 (3.0%)	0/0 (−%)
Permanently discontinued from the study product	0/0 (−%)	0/25 (0.0%)	0/0 (−%)	0/33 (0.0%)	0/0 (−%)
Terminated from the study	0/0 (−%)	0/25 (0.0%)	0/0 (−%)	1/33 (3.0%)	0/0 (−%)
Permanently discontinued from the study product first and then terminated from the study	0/0 (−%)	0/25 (0.0%)	0/0 (−%)	0/33 (0.0%)	0/0 (−%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (30JUN2018,5:32)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − June 30, 2018
Data through : June 30, 2018
Table 4 − Progression to Step 2 by Site

	St.Mary's Clinic	Swaziland	UVRI−IAVI	Verulam	Ward 21
Total Participants Enrolled[1]	29	0	0	0	32
Participants who have been enrolled for 6 weeks or received injection[2]	29	0	0	0	32
Progressed to Step 2	29/29 (100.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	31/32 (96.9%)
Progression Status Pending	0/29 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	1/32 (3.1%)
Did Not Progress to Step 2	0/29 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/32 (0.0%)
Permanently discontinued from the study product	0/29 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/32 (0.0%)
Terminated from the study	0/29 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/32 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/29 (0.0%)	0/0 (−%)	0/0 (−%)	0/0 (−%)	0/32 (0.0%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (30JUN2018,5:32)

HPTN 084 − A Phase 3 Double Blind Safety and Efficacy Study of Long−Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre−Exposure Prophylaxis in HIV−Uninfected Women
Report − June 30, 2018
Data through : June 30, 2018
Table 4 − Progression to Step 2 by Site

	Zengeza
Total Participants Enrolled[1]	20
Participants who have been enrolled for 6 weeks or received injection[2]	18
Progressed to Step 2	17/18 (94.4%)
Progression Status Pending	1/18 (5.6%)
Did Not Progress to Step 2	0/18 (0.0%)
Permanently discontinued from the study product	0/18 (0.0%)
Terminated from the study	0/18 (0.0%)
Permanently discontinued from the study product first and then terminated from the study	0/18 (0.0%)

[1] Inappropriately enrolled participants are excluded.
[2] Participants who did not progress to Step 2 due to HIV infection are not included.

Source: SCHARP (zwang) − /trials/hptn/p084/analysis/atlas/code/open/t_prog2step2.sas, SAS Version 9.4 (30JUN2018,5:32)